Roche dives further into cancer cell therapy with Adaptimmune dealRoche has largely been a spectator on the side lines as other drugmakers have embraced cell therapies for Share XRoche dives further into cancer cell therapy with Adaptimmune dealhttps://pharmaphorum.com/news/roche-dives-further-into-cancer-cell-therapy-with-adaptimmune-deal/
Lilly taps Lycia for protein degrader tech in $1.6bn dealEli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal Share XLilly taps Lycia for protein degrader tech in $1.6bn dealhttps://pharmaphorum.com/news/lilly-taps-lycia-for-protein-degrader-tech-in-1-6bn-deal/
Third strike for GSK/Merck as bintrafusp alfa flubs againGlaxoSmithKline’s big gamble on Merck KGaA’s bintrafusp alfa has gone from bad to worse, after the drug failed Share XThird strike for GSK/Merck as bintrafusp alfa flubs againhttps://pharmaphorum.com/news/third-strike-for-gsk-merck-cancer-alliance-as-bintrafusp-alfa-flubs-again/
BMS buys into AI-designed immune drug from ExscientiaBristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Share XBMS buys into AI-designed immune drug from Exscientiahttps://pharmaphorum.com/news/exscientia/
Ipsen forges $1bn alliance with Exicure on neurodegenerative diseasesIpsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took Share XIpsen forges $1bn alliance with Exicure on neurodegenerative diseaseshttps://pharmaphorum.com/news/ipsen-forges-1bn-alliance-with-exicure-on-neurodegenerative-diseases/
AbbVie, Calico raise their age-related disease alliance funding to $3.5bnAbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases Share XAbbVie, Calico raise their age-related disease alliance funding to $3.5bnhttps://pharmaphorum.com/news/abbvie-calico-raise-their-age-related-disease-alliance-funding-to-3-5bn/
Regeneron, AZ team up on drugs for obesity “superpower” geneAstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at Share XRegeneron, AZ team up on drugs for obesity “superpower” genehttps://pharmaphorum.com/news/regeneron-az-team-up-on-drugs-for-obesity-superpower-gene/
Biogen builds MS pipeline via $125m deal with China’s InnoCareBiogen has moved to shore up its besieged multiple sclerosis franchise by licensing a BTK inhibitor from Chinese Share XBiogen builds MS pipeline via $125m deal with China’s InnoCarehttps://pharmaphorum.com/news/biogen-builds-ms-pipeline-via-125m-deal-with-chinas-innocare/
Novo Nordisk bulks up in rare diseases with $1.2bn Prothena dealDiabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition Share XNovo Nordisk bulks up in rare diseases with $1.2bn Prothena dealhttps://pharmaphorum.com/news/novo-nordisk-bulks-up-in-rare-diseases-with-1-2bn-prothena-deal/
